Clinical trial · Interventional
NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma
Endoscopic NBI Combined With MRI to Guide the Optimization of Clinical Target Volume Delineation in Eccentric Nasopharyngeal Carcinoma
NCT06167109CI-TRIAL-00072174recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, single-center clinical trial in eccentric nasopharyngeal carcinoma (NPC) patients. The aim of this study is to evaluate the efficacy and safety of NBI combined with MRI-guided optimized CTV compared with conventional CTV, and to compare the radiotherapy-related adverse events and quality of life between the two groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma by AJCC V8 Stage | Nasopharyngeal Carcinoma by AJCC v8 Stage | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CTV optimized IMRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Optimized CTV
- description
- The contralateral CTV1 was defined as a subclinical disease consisting of 5mm margin surrounding GTVnx.The CTV2 was defined as potentially involved regions consisting of 5mm margin surrounding CTV1, and contralateral CTV2 only included the pharyngeal recess.
- interventionNames
- Radiation: CTV optimized IMRT
- type
- NO_INTERVENTION
- label
- Conventional CTV
- description
- The CTV1 was defined as GTVnx + 5 mm + entire nasopharynx mucosa .The CTV2 was defined as GTV1+ 5 mm + corresponding anatomical structures.
Primary outcomes (2)
- measure
- Acute adverse reactions
- timeFrame
- 3 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Males and females ≥18 years of age; 2. ECOG Performance Status 0,1 or 2; 3. Pathologically diagnosed as nasopharyngeal carcinoma; 4. Pretreatment nasopharynx and neck MRI imaging; 5. Nasopharyngeal suspected lesions were examined by NBI endoscopy; 6. Meeting the definition of eccentric NPC with ipsilateral (affected side) staging of T1-4 and contralateral (healthy side) staging of T0; 7. Patients evaluated without contraindications to radiotherapy; 8. Voluntary participation in clinical research, and signed informed consent. Exclusion Criteria: 1. Patients who did not successfully undergo all three examinations (MRI, NBI, and endoscopic biopsy); 2. Other rare pathological types, such as adenocarcinoma; 3. Patients with tumor invasion of the clivus; 4. Patients whose contralateral retropharyngeal lymph nodes met the diagnostic criteria; 5. Invasion of paranasal sinuses (except simple sphenoid invasion).
References
Publications (1)
- DERIVEDSong Y, Wang Y, Yang M, Yu X, Li M, Long B, Shu X, Zhang X, Wang F, Wang C, Hu M, Sui JD, Wang Y. Individualization of clinical target volume delineation in eccentric nasopharyngeal carcinoma: a prospective comparative study. Front Oncol. 2025 Aug 4;15:1587764. doi: 10.3389/fonc.2025.1587764. eCollection 2025. PMID 40831921